Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Mike M who wrote (3419)	12/7/2000 3:03:07 AM
From: george eberting	Read Replies (1) \| Respond to of 5582

Boy, I surely haven't seen any of it. But thanks for setting the record straight.

To: Mike M who wrote (3419)	12/7/2000 8:43:27 AM
From: DanZ	Read Replies (1) \| Respond to of 5582

Zacks zacks.com and Yahoo Finance, which gets its data from Zacks, have updated their database to properly categorize Gum Tech in the Healthcare sector, Biotechnology and Drug industry. biz.yahoo.com biz.yahoo.com When someone does a scan now, they will find that GUMM is significantly undervalued based on the price to sales and price to book as compared to other companies in the Biotechnology & Drug industry. Here is the data. Price to sales: Biotechnology & Drugs - 22.2 Food Processing - 1.6 Gum Tech - 3.6 Price to book: Biotechnology & Drugs - 11.6 Food Processing - 10.8 Gum Tech - 5.1 This data shows how important it is that GUMM be properly classified. Market Guide is in the process of updating their database as well. As one of our short "friends" said recently, Gum Tech doesn't belong in the biotechnology and drug industry. I guess he would say that it's easy to fool Zacks.